Trial Profile
Phase I Study to Assess the Optimal Dose for Pazopanib in Combination With Capecitabine in Patients With HER2-negative, Metastatic Breast Cancer (PazoX)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Pazopanib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Acronyms PazoX
- 16 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Dec 2011 New trial record